Lurbinectedin

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 220 publications

Ultramutagenesis through combined Msh2 depletion and proofreading-deficient DNA polymerase ε expression enhances small molecule target identification in forward genetic screens.

Ultramutagenesis through combined Msh2 depletion and proofreading-deficient DNA polymerase ε expression enhances small molecule target identification in forward genetic screens.

Journal: bioRxiv : the preprint server for biology
Published: July 10, 2026

Update 2026: Management of Small Cell Lung Cancer.

Update 2026: Management of Small Cell Lung Cancer.

Journal: Lung
Published: June 05, 2026

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore-A Review of Recent Therapeutic Advances.

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore-A Review of Recent Therapeutic Advances.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 02, 2026

Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenografts.

Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenografts.

Journal: Cancer research communications
Published: May 25, 2026

Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies.

Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies.

Journal: Critical reviews in oncology/hematology
Published: April 25, 2026

Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?

Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 24, 2026

Outcomes of Lurbinectedin in Central Nervous System Metastases of Small Cell Lung Cancer: A Single-Institution Retrospective Case Series.

Outcomes of Lurbinectedin in Central Nervous System Metastases of Small Cell Lung Cancer: A Single-Institution Retrospective Case Series.

Journal: Reports (MDPI)
Published: April 23, 2026

A decade of progress in small-cell lung cancer (2015-2025): a narrative review.

A decade of progress in small-cell lung cancer (2015-2025): a narrative review.

Journal: European journal of clinical pharmacology
Published: April 21, 2026

Lurbinectedin in treating CNS metastases from small cell neuroendocrine prostate cancer-a case report.

Lurbinectedin in treating CNS metastases from small cell neuroendocrine prostate cancer-a case report.

Journal: Frontiers in oncology
Published: March 27, 2026

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Journal: Investigational new drugs
Published: March 12, 2026

Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis.

Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 10, 2026

Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework.

Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework.

Journal: Therapeutic advances in medical oncology
Published: February 10, 2026
Showing 1-12 of 220

Last Updated: 09/26/2026